BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on Thursday, August 12, 2021.

Amedisys, Inc. reported its financial results for the three and six-month periods ended June 30, 2021.

RxSight, Inc., an ophthalmic medical device company, today announced the closing of its initial public offering of 7,350,000 shares of common stock on August 3, 2021, as well as the partial exercise of the underwriters’ option to purchase an additional 898,594 additional shares of common stock,

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the second quarter ended June 30, 2021.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a general business update.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights.

Reported net sales increased 15.1% to $225.9 million, and constant currency net sales increased 7.8%, reflecting growth across all product categories.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August: